Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
Status:
Completed
Trial end date:
2018-05-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo-controlled, parallel-design study. The study
will enroll approximately 210 adult male and female subjects with stage 3 or 4 chronic kidney
disease and metabolic acidosis. The study dosing (TRC101 or placebo) will continue for 12
weeks once daily.
The maximum study duration is anticipated to be up to 16 weeks.